Protara director receives 31,000 stock options

Protara Therapeutics director Roger Garceau received a grant of stock options for 31,000 shares of Common Stock.

Rhea-AI Filing Summary

Protara Therapeutics director Roger Garceau received a grant of stock options for 31,000 shares of Common Stock. The options have an exercise price of $3.94 per share, expire on June 14, 2036, and vest in full on the first anniversary of the June 15, 2026 grant date or upon a Change of Control, subject to continued board service.

Insider Trade Summary

Grant/Award: 31,000 shares

Grant/Award 1 txn

Insider GARCEAU ROGER

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	31,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 31,000 contracts (Direct)

Footnotes (1)

1. F1. 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control.

Key Figures

Options granted: 31,000 options Exercise price: $3.94 per share Underlying shares: 31,000 shares +2 more

5 metrics

Options granted 31,000 options Stock Option (Right to Buy) grant on June 15, 2026

Exercise price $3.94 per share Exercise price of granted stock options

Underlying shares 31,000 shares Common Stock underlying the options

Total options after grant 31,000 options Total derivative securities held after this transaction

Option expiration date June 14, 2036 Expiration of stock options if unexercised

Key Terms

Stock Option (Right to Buy), Annual Grant, Change of Control, exercise price

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Annual Grant financial

"The shares subject to the Annual Grant will vest in full"

Change of Control financial

"and will vest in full upon a Change of Control"

A change of control occurs when the ownership or management of a company shifts significantly, such as through a sale, merger, or acquisition, resulting in new leadership or ownership structure. This change can impact the company's direction and decision-making, which is important for investors because it may affect the company's stability, strategy, and future prospects.

exercise price financial

"conversion_or_exercise_price: 3.9400"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Protara Therapeutics (TARA) director Roger Garceau receive in this Form 4?

Roger Garceau received a grant of stock options covering 31,000 shares of Protara Therapeutics Common Stock. These options were awarded as compensation and are not an open-market purchase or sale of existing shares.

What is the exercise price of Roger Garceau’s new Protara (TARA) stock options?

The granted stock options have an exercise price of $3.94 per share. This means Garceau can buy Protara Common Stock at $3.94 per share once the options are vested and exercised before expiration.

When do Roger Garceau’s Protara (TARA) stock options vest?

The options from the Annual Grant vest in full on the first anniversary of the June 15, 2026 grant date. Vesting is subject to his continuous service as a board member or will accelerate upon a Change of Control.

When do the Protara (TARA) stock options granted to Roger Garceau expire?

These stock options expire on June 14, 2036, if not exercised earlier. After this expiration date, Garceau can no longer exercise the options to purchase Protara Common Stock at the $3.94 exercise price.

How many Protara (TARA) options does Roger Garceau hold after this transaction?

Following this grant, Garceau holds 31,000 stock options according to the filing. This entire amount reflects the new Annual Grant, with no additional derivative holdings shown in this specific disclosure.

Is this Protara (TARA) Form 4 a market purchase or sale of shares?

No, this Form 4 reports a compensation-related stock option grant, not a market trade. The transaction code is “A,” indicating a grant or award acquisition of derivative securities rather than an open-market buy or sell.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/16/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GARCEAU ROGER

(Last) (First) (Middle)

C/O PROTARA THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, 3RD FLOOR

(Street)

NEW YORK NEW YORK 10010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Protara Therapeutics, Inc. [ TARA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.94	06/15/2026		A		31,000		06/15/2027(1)	06/14/2036	Common Stock	31,000	$0	31,000	D

Explanation of Responses:

1. 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control.

Remarks:

	/s/ Mary Grendell, Attorney-in-fact	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)